Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fx-1006A in non-V30M transthyretin amyloidosis
2007-006791-12Phase 2Completed
- Sponsor
- FoldRx Pharmaceuticals
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tafamidis in transthyretin amyloidosis (ATTR), sponsored by FoldRx Pharmaceuticals. Primary endpoint: Transthyretin stabilization at Week 6. Started Jan 2008; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on 2007-006791-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006791-12.